Fidelis Capital Partners, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Fidelis Capital Partners, LLC
- $702 Billion
- Q2 2024
A detailed history of Fidelis Capital Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Fidelis Capital Partners, LLC holds 534 shares of REGN stock, worth $540,845. This represents 0.08% of its overall portfolio holdings.
Number of Shares
534
Previous 420
27.14%
Holding current value
$540,845
Previous $404 Million
41.05%
% of portfolio
0.08%
Previous 0.06%
Shares
4 transactions
Others Institutions Holding REGN
# of Institutions
1,464Shares Held
84.4MCall Options Held
907KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$9.11 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$8.55 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$8.38 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.9 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$4.7 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $109B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...